Workflow
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
ALNYAlnylam Pharmaceuticals(ALNY) ZACKS·2024-11-01 14:36

Alnylam Pharmaceuticals (ALNY) reported third-quarter 2024 adjusted loss of 50 cents per share, which matched the Zacks Consensus Estimate. The company had recorded earnings of 1.74pershareintheyear−agoquarter.Theadjustedfigureexcludeditemslikestock−basedcompensationexpensesandrealizedandunrealizedlossonmarketableequitysecurities.Alnylamrecordedtotalrevenuesof1.74 per share in the year-ago quarter. The adjusted figure excluded items like stock-based compensation expenses and realized and unrealized loss on marketable equity securities.Alnylam recorded total revenues of 500.9 million in the quarter, which missed the Zacks Consensus Estimate of $529 million. In the year-ago quarter, total ...